reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
用于治疗 HIV 诊所兴奋剂使用的 reSET:护理优化支持治疗依从性 (COSTA)
基本信息
- 批准号:10553554
- 负责人:
- 金额:$ 93.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS/HIV problemAbstinenceAcquired Immunodeficiency SyndromeAdoptionAdultAfrican AmericanAfrican American populationAgeAreaBlack PopulationsBlack raceBloodCaringClinicCognitive TherapyCommunitiesComputer softwareConsentContinuity of Patient CareDiagnosisDiseaseDrug Use DisorderDrug usageEffectivenessEnvironmentEpidemicEthnic OriginEthnic groupFDA approvedFaceFoundationsHIVHIV InfectionsHIV diagnosisHealthHealth InsuranceHealthcareHealthcare SystemsHepatitisImprisonmentInterventionLaboratoriesLatinxLettersLos AngelesMaintenanceMediator of activation proteinMedicalMinority MenModelingNot Hispanic or LatinoOutcomeOutpatientsPain ClinicsParticipantPatientsPersonsPharmaceutical PreparationsPharmacotherapyPopulationPsychological reinforcementPsychosocial Assessment and CarePublic HealthRaceRandomizedReach Effectiveness Adoption Implementation and MaintenanceReportingRiskSexually Transmitted DiseasesSiteSocial supportSoftware DesignSpine painStimulantSubstance Use DisorderTestingTherapeuticUnited StatesUnited States National Institutes of HealthUrineViralViral Load resultVisitantiretroviral therapyarmbasecontingency managementcost effectivenessdesigneconomic impacteffectiveness testingethnic diversityethnic minorityexperiencefollow-uphandheld mobile devicehealth care settingshigh risk sexual behaviorimprovedmedication compliancemen who have sex with menoff-label usepreventprimary outcomepsychosocialracial and ethnicrecruitsecondary outcomesexual minorityskillsstimulant usestimulant use disordersubstance use treatmenttherapy adherencetooltransmission processtreatment adherencetreatment as preventiontreatment as usualtreatment centertreatment optimizationtreatment programtreatment servicesvirtual
项目摘要
Abstract
In 2019 men who have sex with men (MSM) accounted for 70% of the 34,800 new HIV diagnoses and 66%
of the 1.2 million total HIV infections in the United States. Among this high priority population, MSM living with
HIV, stimulant use is a major barrier to achieving viral load control, necessary for reducing HIV transmission
and improving long term health outcomes. Additionally, having HIV and substance use disorder diagnoses, as
well as being racial/ethnic minority MSM, exacerbate the barriers to accessing and completing in-person drug
treatment services. reSET is the first FDA approved prescription mobile therapeutic software designed to treat
substance use disorders in adults. In patients with a primary diagnosis of stimulant use disorder, reSET has
been found efficacious in reducing stimulant use, both for patients who are already in drug treatment and as a
standalone substance use treatment for incarcerated persons. However, reSET has not been tested in any
medical settings, including HIV care settings, as an all-virtual SUD treatment for patients living with HIV. To
effectively mitigate the HIV epidemic among ethnically diverse MSM living with HIV, we propose a two-arm
RCT of an all-virtual 12-week stimulant disorder treatment for MSM living with HIV who are on antiretroviral
therapy (ART). The study will include 426 racial/ethnically diverse MSM (~50% African American and ~23%
Latinx). Participants will be patients of the AIDS Healthcare Foundation (AHF) HIV treatment centers (10
participating clinics) located in four US metro areas with AHF’s highest numbers of HIV cases with stimulant
use (Atlanta, Dallas/Fort Worth, Fort Lauderdale and Los Angeles). Participants with moderate to severe
stimulant use disorder will be randomized to two conditions: (1) referral to outpatient substance use disorder
treatment (treatment as usual/ control condition) or (2) reSET (experimental condition) to: (Aim 1a) test the
effectiveness of standalone all-virtual reSET in achieving lower stimulant use across 3-, 9- and 15-months
compared to TAU; (Aim 1b) test the effectiveness of standalone all-virtual reSET in increasing the likelihood of
viral suppression across the 3-, 9- and 15-months follow-up periods compared to TAU; (Aim 2) examine the
moderating effect of race/ethnicity (Blacks/African Americans, Latinx, and Whites) on the relationship between
condition and stimulant use (primary outcome) and VL suppression (secondary outcome); and (Aim 3) to
evaluate in the context of the RE-AIM framework, the reach, effectiveness, adoption, implementation,
economic impact, and implementation maintenance of the experimental treatment within AHF. If found
effective, reSET implemented in conjunction ART could, present a major scalable advancement in optimizing
‘treatment as prevention’ among sexual minorities living with HIV and stimulant use disorder.
摘要
2019年,男男性行为者(MSM)占34,800例新艾滋病毒诊断的70%,占66%。
在美国120万艾滋病感染者中。在这一高度优先的人群中,
艾滋病毒,兴奋剂的使用是实现病毒载量控制的主要障碍,这是减少艾滋病毒传播所必需的
改善长期健康状况。此外,有艾滋病毒和物质使用障碍的诊断,
以及种族/少数民族的男男性接触者,加剧了获得和完成面对面药物的障碍
治疗服务。reSET是第一个FDA批准的处方移动的治疗软件,
成人物质使用障碍。在初步诊断为兴奋剂使用障碍的患者中,
已经发现有效减少兴奋剂的使用,无论是对已经在药物治疗的患者,
为被监禁者提供独立的药物使用治疗。然而,reSET尚未在任何
医疗机构,包括艾滋病毒护理机构,作为艾滋病毒感染者的全虚拟SUD治疗。到
有效地减轻艾滋病毒流行的种族多样化的男男性接触者感染艾滋病毒,我们提出了一个双臂
对正在接受抗逆转录病毒治疗的HIV感染MSM进行全虚拟12周刺激性障碍治疗的RCT
治疗(ART)。这项研究将包括426名种族/民族多样化的男男性行为者(约50%为非洲裔美国人,约23%为男性)。
Latinx)。参与者将是艾滋病保健基金会(AHF)艾滋病毒治疗中心的患者(10
参与诊所)位于美国四个大都市地区,AHF的兴奋剂艾滋病毒病例数最高
使用(亚特兰大、达拉斯/沃斯堡、劳德代尔堡和洛杉矶)。中度至重度受试者
兴奋剂使用障碍将随机分为两种情况:(1)转诊到门诊物质使用障碍
治疗(照常治疗/对照条件)或(2)重新设置(实验条件),以:(目的1a)测试
独立全虚拟reSET在3个月、9个月和15个月内实现较低兴奋剂使用的有效性
与TAU相比;(目标1b)测试独立全虚拟重置在增加以下可能性方面的有效性
与TAU相比,在3个月、9个月和15个月随访期间的病毒抑制;(目的2)检查
种族/民族(黑人/非裔美国人、拉丁裔和白人)对
条件和兴奋剂使用(主要结局)和VL抑制(次要结局);以及(目标3)
在RE-AIM框架的背景下评估,覆盖范围,有效性,采用,实施,
经济影响,并在AHF内实施维持实验治疗。如果发现
与ART结合实施的有效的reSET可以在优化方面呈现出重大的可扩展的进步,
在感染艾滋病毒和兴奋剂使用障碍的性少数群体中,“治疗即预防”。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adam Wayne Carrico其他文献
Adam Wayne Carrico的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adam Wayne Carrico', 18)}}的其他基金
Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV.
建立美国国家队列以改善使用兴奋剂的艾滋病毒男性感染者的病毒抑制。
- 批准号:
10675863 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Relationship between methamphetamine use, viral reservoir dynamics and clinical progression in treated HIV infection
甲基苯丙胺使用、病毒库动态与治疗艾滋病毒感染的临床进展之间的关系
- 批准号:
10683495 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Supporting Treatment Adherence for Resilience and Thriving (START): A mHealth intervention to improve ART adherence for HIV-positive stimulant-using men
支持治疗依从性以促进复原力和繁荣 (START):一项移动医疗干预措施,旨在提高使用兴奋剂的 HIV 阳性男性的 ART 依从性
- 批准号:
10895784 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Supporting Treatment Adherence for Resilience and Thriving (START): A mHealth intervention to improve ART adherence for HIV-positive stimulant-using men
支持治疗依从性以促进复原力和繁荣 (START):一项移动医疗干预措施,旨在提高使用兴奋剂的 HIV 阳性男性的 ART 依从性
- 批准号:
10898254 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Optimizing HIV prevention for highly vulnerable methamphetamine-using sexual minority men
优化对高度脆弱的使用甲基苯丙胺的性少数男性的艾滋病毒预防
- 批准号:
10462053 - 财政年份:2022
- 资助金额:
$ 93.23万 - 项目类别:
Optimizing HIV prevention for highly vulnerable methamphetamine-using sexual minority men
优化对高度脆弱的使用甲基苯丙胺的性少数男性的艾滋病毒预防
- 批准号:
10606596 - 财政年份:2022
- 资助金额:
$ 93.23万 - 项目类别:
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
调查抑郁症对神经免疫目标影响的治疗研究 (TRIDENT)
- 批准号:
10700126 - 财政年份:2021
- 资助金额:
$ 93.23万 - 项目类别:
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
调查抑郁症对神经免疫目标影响的治疗研究 (TRIDENT)
- 批准号:
10369905 - 财政年份:2021
- 资助金额:
$ 93.23万 - 项目类别:
Optimizing PrEP adherence in sexual minority men who use stimulants
优化使用兴奋剂的性少数男性的 PrEP 依从性
- 批准号:
10404091 - 财政年份:2020
- 资助金额:
$ 93.23万 - 项目类别:
Optimizing PrEP adherence in sexual minority men who use stimulants
优化使用兴奋剂的性少数男性的 PrEP 依从性
- 批准号:
10894531 - 财政年份:2020
- 资助金额:
$ 93.23万 - 项目类别:
相似海外基金
StuDy AimED at Increasing AlCohol AbsTinEnce (DEDICATE)
旨在提高酒精戒断率的研究(奉献)
- 批准号:
10577022 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
A Controlled Study of Extended Cannabis Abstinence in Major Depression
重度抑郁症患者长期吸食大麻的对照研究
- 批准号:
478313 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Operating Grants
Exercised-induced modulation of insular cortex microcircuitry during alcohol abstinence
戒酒期间运动诱导的岛叶皮质微电路调节
- 批准号:
10748763 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Prapela™ SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.
Prapela™ SVS:一种经济高效的随机振动触觉刺激装置,可改善患有新生儿戒断综合征的婴儿的临床过程。
- 批准号:
10837421 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Enforced alcohol abstinence: does it reduce reoffending?
强制戒酒:会减少再犯罪吗?
- 批准号:
ES/X003566/1 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Fellowship
Neurobiological impact of acute digital media abstinence among drug using college students
吸毒大学生急性数字媒体戒断的神经生物学影响
- 批准号:
10677380 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Single-cell whole brain imaging of nicotine intoxication, dependence, and abstinence
尼古丁中毒、依赖和戒断的单细胞全脑成像
- 批准号:
10588509 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Understanding recovery from alcohol use disorder: Longitudinal observation of two voluntary temporary abstinence periods
了解酒精使用障碍的恢复:两个自愿临时戒酒期的纵向观察
- 批准号:
10740677 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Sleep Disturbances During Cocaine Abstinence, Dopamine Adaptations, and Motivation for Cocaine
可卡因戒断期间的睡眠障碍、多巴胺适应和可卡因动机
- 批准号:
10681668 - 财政年份:2023
- 资助金额:
$ 93.23万 - 项目类别:
Transcriptional adaptations driving the intensification of alcohol-seeking in dependent rats undergoing prolonged abstinence
转录适应导致长期戒酒的依赖性大鼠对酒精的渴求加剧
- 批准号:
10540014 - 财政年份:2022
- 资助金额:
$ 93.23万 - 项目类别: